text: Rhino orbital cerebral mucormycosis in COVID 19 A systematic review Since the onset of COVID 19 pandemic parallel opportunistic infections have also been emerging as another disease spectrum Among all these opportunistic infection mucormycosis has become a matter of concern with its rapid increase of cases with rapid spread as compared to pre COVID 19 era Cases have been reported in post COVID 19 related immune suppression along with the presence of comorbidity which adds on the deadly outcome There is no systematic review addressing the issue of COVID 19 associated mucormycosis This is the first systematic review of published studies of mucormycosis associated with COVID 19 The aim was to analyze the real scenario of the disease statement including all the published studies from first November 2019 to 30th June to analyze the contemporary epidemiology clinical manifestations risk factor prognosis and treatment outcome of COVID 19 associated rhino orbito cerebral mucormycosis A comprehensive literature search was done in following databases namely PubMed Google Scholar Scopus and EMBASE using keywords mucormycosis rhino orbital cerebral mucormycosis COVID 19 and SARS CoV 2 from November 01 2019 to June 30 2021 Our study shows that while corticosteroids have proved to be lifesaving in severe to critical COVID 19 patients its indiscriminate use has come with its price of rhino orbito cerebral mucormycosis epidemic especially in India especially in patients with preexisting diabetes mellitus with higher mortality Corticosteroid use should be monitored and all COVID 19 patients should be closely evaluated monitored for sequelae of immunosuppression following treatment 